Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears
Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Read More 6 minute read Pharma Industry News How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care. bySoujanya RaviFebruary 6, 2026